Edition:
United States

Soleno Therapeutics Inc (SLNO.OQ)

SLNO.OQ on NASDAQ Stock Exchange Capital Market

3.10USD
22 Jun 2018
Change (% chg)

$0.77 (+33.05%)
Prev Close
$2.33
Open
$3.40
Day's High
$3.60
Day's Low
$2.72
Volume
1,929,815
Avg. Vol
25,968
52-wk High
$3.70
52-wk Low
$1.35

Chart for

About

Soleno Therapeutics, Inc., formerly Capnia, Inc., is a healthcare company that develops and commercializes neonatology devices and diagnostics. The Company also has a therapeutics platform based on its proprietary technology for precision metering of gas flow. The Company offers products, such as CoSense end-tidal carbon... (more)

Overall

Beta: --
Market Cap(Mil.): $23.39
Shares Outstanding(Mil.): 9.58
Dividend: --
Yield (%): --

Financials

  SLNO.OQ Industry Sector
P/E (TTM): -- 32.19 32.74
EPS (TTM): -3.40 -- --
ROI: -68.04 13.89 14.38
ROE: -98.99 16.72 16.08

BRIEF-Soleno Therapeutics Q1 Loss Per Share $0.19

* SOLENO THERAPEUTICS PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 16 2018

BRIEF-Soleno Therapeutics Says QTRLY Loss Per Share From Continuing Operations $0.17 - SEC Filing

* SOLENO THERAPEUTICS SAYS QTRLY LOSS PER SHARE FROM CONTINUING OPERATIONS $0.17 - SEC FILING

May 16 2018

BRIEF-Soleno Therapeutics Announces Initiation Of Phase III Clinical Trial Of DCCR In Prader-Willi Syndrome

* SOLENO THERAPEUTICS ANNOUNCES INITIATION OF PHASE III CLINICAL TRIAL OF DCCR IN PRADER-WILLI SYNDROME

May 14 2018

BRIEF-Soleno Therapeutics Reports Q4 Loss Per Share $0.43

* Q4 LOSS PER SHARE $0.39 FROM CONTINUING OPERATIONS Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

Apr 02 2018

BRIEF-Soleno Therapeutics Announces Successful End-Of-Phase II Meeting With FDA For DCCR In Prader-Willi Syndrome

* SOLENO THERAPEUTICS ANNOUNCES SUCCESSFUL END-OF-PHASE II MEETING WITH FDA FOR DCCR IN PRADER-WILLI SYNDROME

Feb 20 2018

BRIEF-Soleno Therapeutics Files For Resale Of Up To 14.2 Mln Shares

* SOLENO THERAPEUTICS INC FILES FOR RESALE OF UP TO 14.2 MILLION SHARES OF COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILING Source text: (http://bit.ly/2DKTA0l) Further company coverage:

Jan 29 2018

BRIEF-Jack W. Schuler Living Trust Reports 13.4 Pct Stake In Soleno Therapeutics As Of December 15

* JACK W. SCHULER LIVING TRUST REPORTS 13.4 PERCENT STAKE IN SOLENO THERAPEUTICS INC AS OF DECEMBER 15 - SEC FILING Source text: (http://bit.ly/2mkVVHQ) Further company coverage:

Jan 12 2018

BRIEF-Soleno Therapeutics Says Board Resolved To Decrease Size Of Board From Ten To Seven

* SOLENO THERAPEUTICS SAYS ON JAN 2, BOARD RESOLVED TO DECREASE SIZE OF BOARD FROM TEN DIRECTORS TO SEVEN DIRECTORS - SEC FILING Source text for Eikon: (http://bit.ly/2F27EUa) Further company coverage:

Jan 05 2018

BRIEF-Birchview Capital LP Reports A 6.17 Pct Passive Stake In Soleno Therapeutics

* BIRCHVIEW CAPITAL LP REPORTS A 6.17 PCT PASSIVE STAKE IN SOLENO THERAPEUTICS AS OF DEC 15 - SEC FILING Source text for Eikon: (http://bit.ly/2DT2Zn3) Further company coverage:

Dec 26 2017

Earnings vs. Estimates